Comparison between bimatoprost and latanoprost-timolol fixed combination for efficacy and safety after switching patients from latanoprost

References

• ResnikoffSPascoliniDEtya’aleDGlobal data on visual impairment in the year 2002Bull World Health Organ2004821184485115640920
   PubMed Web of Science ®Google Scholar
• QuigleyHABromanATThe number of people with glaucoma worldwide in 2010 and 2020Br J Ophthalmol200690326226716488940
   PubMed Web of Science ®Google Scholar
• LeskeMCConnellAMWuSYHymanLGSchachatAPRisk factors for open-angle glaucoma. The Barbados Eye StudyArch Ophthalmol199511379189247605285
   PubMedGoogle Scholar
• ColemanALMigliorSRisk factors for glaucoma onset and progressionSurv Ophthalmol200853Suppl 1S3S1019038621
   PubMed Web of Science ®Google Scholar
• KassMAHeuerDKHigginbothamEJThe Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucomaArch Ophthalmol2002120670171312049574
   PubMed Web of Science ®Google Scholar
• HeijlALeskeMCBengtssonBHusseinMMeasuring visual field progression in the Early Manifest Glaucoma TrialActa Ophthalmol Scand200381328629312780410
   PubMedGoogle Scholar
• LichterPRMuschDCGillespieBWInterim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgeryOphthalmology2001108111943195311713061
   PubMed Web of Science ®Google Scholar
• AGIS InvestigatorsThe Advanced Glaucoma Intervention Study (AGIS): 9. Comparison of glaucoma outcomes in black and white patients within treatment groupsAm J Ophthalmol2001132331132011530042
   PubMed Web of Science ®Google Scholar
• HeijlALeskeMCBengtssonBHymanLHusseinMReduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma TrialArch Ophthalmol2002120101268127912365904
   PubMed Web of Science ®Google Scholar
• The Japan Glaucoma Society Guidelines for Glaucoma (3rd Edition)Nihon Ganka Gakkai Zasshi20121161346 Japanese22352070
   PubMedGoogle Scholar
• SharifNAWilliamsGWKellyCRBimatoprost and its free acid are prostaglandin FP receptor agonistsEur J Pharmacol20014322–321121311740958
   PubMed Web of Science ®Google Scholar
• BrubakerRFMechanism of action of bimatoprost (Lumigan)Surv Ophthalmol200145Suppl 4S347S35111434937
   PubMed Web of Science ®Google Scholar
• GandolfiSSimmonsSTSturmRChenKVanDenburghAMThree-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertensionAdv Ther200118311012111571823
   PubMed Web of Science ®Google Scholar
• HigginbothamEJSchumanJSGoldbergIOne-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertensionArch Ophthalmol2002120101286129312365906
   PubMed Web of Science ®Google Scholar
• SatoSHirookaKBabaTEfficacy and safety of switching from topical latanoprost to bimatoprost in patients with normal-tension glaucomaJ Ocul Pharmacol Ther201127549950221790301
   PubMed Web of Science ®Google Scholar
• VenturaMPSahebNESolariHPCost considerations of the new fixed combinations for glaucoma medical therapyJ Clin Pharm Ther200530325125415896242
   PubMed Web of Science ®Google Scholar
• HigginbothamEJFeldmanRStilesMDubinerHLatanoprost and timolol combination therapy vs monotherapy: one-year randomized trialArch Ophthalmol2002120791592212096962
   PubMed Web of Science ®Google Scholar
• MagachoLReisRShettyRKSantosLCAvilaMPEfficacy of latanoprost or fixed-combination latanoprost-timolol in patients switched from a combination of timolol and a nonprostaglandin medicationOphthalmology2006113344244516458964
   PubMed Web of Science ®Google Scholar
• KonstasAGBanyaiLBlaskKDIntraocular pressure and safety in glaucoma patients switching to latanoprost/timolol maleate fixed combination from mono- and adjunctive therapiesJ Ocul Pharmacol Ther200420537538215650512
   PubMed Web of Science ®Google Scholar
• DiestelhorstMLarssonLIA 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual componentsOphthalmology20061131707616263174
   PubMed Web of Science ®Google Scholar
• InoueKOkayamRHigaROcular hypotensive effects and safety over 3 months of switching from an unfixed combination to latanoprost 0.005%/timolol maleate 0.5% fixed combinationJ Ocul Pharmacol Ther201127658158722011049
   PubMed Web of Science ®Google Scholar
• ManniGCentofantiMParravanoMOddoneFBucciMGA 6-month randomized clinical trial of bimatoprost 0.03% versus the association of timolol 0.5% and latanoprost 0.005% in glaucomatous patientsGraefes Arch Clin Exp Ophthalmol2004242976777015241611
   PubMed Web of Science ®Google Scholar
• RossettiLKarabatsasCHTopouzisFComparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressureOphthalmology2007114122244225117459480
   PubMed Web of Science ®Google Scholar
• MesciCAydinNErbilHHTwenty-four-hour intraocular pressure control with latanoprost-timolol-fixed combination versus bimatoprost in patients who switched from timololJ Glaucoma201120847748121048508
   PubMed Web of Science ®Google Scholar
• FacioACReisASVidalKSA comparison of bimatoprost 0.03% versus the fixed-combination of latanoprost 0.005% and timolol 0.5% in adult patients with elevated intraocular pressure: an eight-week, randomized, open-label trialJ Ocul Pharmacol Ther200925544745119860553
   PubMed Web of Science ®Google Scholar
• InoueKFujimotoTHigaREfficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapyClin Ophthalmol2012677177522693419
   PubMedGoogle Scholar
• VarmaRHwangLJGrundenJWBeanGWUsing diurnal intraocular pressure fluctuation to assess the efficacy of fixed-combination latanoprost/timolol versus latanoprost or timolol monotherapyBr J Ophthalmol2010941808419692375
   PubMed Web of Science ®Google Scholar
• PalmbergPKimEEKwokKKTresslerCSA 12-week, randomized, double-masked study of fixed combination latanoprost/timolol versus latanoprost or timolol monotherapyEur J Ophthalmol201020470871820099236
   PubMed Web of Science ®Google Scholar
• LazaridouMNMontgomeryDMHoWOJaberooDChanges in intraocular pressure following a switch from latanoprost monotherapy to latanoprost/timolol fixed combination therapy in patients with primary open-angle glaucoma or ocular hypertension: results from a clinical practice databaseCurr Med Res Opin200824102725272818713491
   PubMed Web of Science ®Google Scholar
• KonstasAGBoboridisKTzetziDTwenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapyArch Ophthalmol2005123789890216009829
   PubMedGoogle Scholar
• QuarantaLBiagioliERivaIProstaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysisJ Ocul Pharmacol Ther201329438238923231442
   PubMed Web of Science ®Google Scholar
• HuangHLSunXHXiaoMComparison of intraocular pressure reducing effects of three prostaglandin eyedrops in open-angle glaucomaZhonghua Yan Ke Za Zhi2011472109113 Chinese21426839
   PubMedGoogle Scholar
• CassonRJLiuLGrahamSLEfficacy and safety of bimatoprost as replacement for latanoprost in patients with glaucoma or ocular hypertension: a uniocular switch studyJ Glaucoma200918858258819826386
   PubMed Web of Science ®Google Scholar
• KashiwagiKEfficacy and safety of switching to travoprost/timolol fixed-combination therapy from latanoprost monotherapyJpn J Ophthalmol201256433934522581454
   PubMed Web of Science ®Google Scholar
• ChiselitaDAntohiIMedvichiRDanielescuCComparative analysis of the efficacy and safety of latanoprost, travoprost and the fixed combination timolol-dorzolamide; a prospective, randomized, masked, cross-over design studyOftalmologia20054933945 Romanian16408674
   PubMedGoogle Scholar
• MoisseievEKurtzSLazarMShemeshGIntraocular pressure reduction using a fixed combination of timolol maleate 0.5% and brimonidine tartrate 0.2% administered three times dailyClin Ophthalmol201371269127323836956
   PubMedGoogle Scholar
• QuarantaLPizzolanteTRivaITwenty-four-hour intraocular pressure and blood pressure levels with bimatoprost versus latanoprost in patients with normal-tension glaucomaBr J Ophthalmol20089291227123118586898
   PubMed Web of Science ®Google Scholar
• ShimazakiJHanadaKYagiYChanges in ocular surface caused by antiglaucomatous eyedrops: prospective, randomised study for the comparison of 0.5% timolol v 0.12% unoprostoneBr J Ophthalmol200084111250125411049949
   PubMed Web of Science ®Google Scholar
• OhtsukiMYokoiNMoriKAdverse effects of beta-blocker eye drops on the ocular surfaceNihon Ganka Gakkai Zasshi2001105314915411280872
   PubMedGoogle Scholar
• ValenteCIesterMCorsiERolandoMSymptoms and signs of tear film dysfunction in glaucomatous patientsJ Ocul Pharmacol Ther201127328128521557633
   PubMed Web of Science ®Google Scholar
• IwaseASuzukiYAraieMThe prevalence of primary open-angle glaucoma in Japanese: the Tajimi StudyOphthalmology200411191641164815350316
   PubMed Web of Science ®Google Scholar
• HolloGVuorinenJTuominenJFixed-dose combination of tafluprost and timolol in the treatment of open-angle glaucoma and ocular hypertension: comparison with other fixed-combination productsAdv Ther201431993294425213118
   PubMed Web of Science ®Google Scholar